5 completed, 3 unknown, 1 enrolling by invitation. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Unknown 3, Enrolling by invitation 1 |
| Phase 2 | 5 | Unknown 3, Completed 1, Enrolling by invitation 1 |
Follow Primary Open Angle Glaucoma: new trials by email Literature Review of Primary Open Angle Glaucoma trials Research Report on Primary Open Angle Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical Insulin for Glaucoma (TING2) EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma | Phase 1 / Phase 2 | Enrolling by invitation | Stanford University | 90 | 2026-09-10 | 2026-10-13 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution - Ocular Hypertension, Primary Open Angle Glaucoma | Phase 1 | Completed | Aerpio Therapeutics | 91 | 2019-05-02 | 2020-02-25 |
| Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy TGF-β2 antisense oligonucleotide, Trabeculectomy - Primary Open Angle Glaucoma | Phase 1 | Completed | Isarna Therapeutics GmbH | 13 | 2015-04-01 | 2018-02-28 |
| Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion. Pulsed Electromagnetic Field Therapy, Seawater eyedrops - Primary Open Angle Glaucoma, Hypertension Ocular | Phase 1 / Phase 2 | Unknown | American Society Of Thermalism And Climatology Inc | 100 | 2014-11-01 | 2015-06-23 |
| A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension VISION5 Product - Ocular Hypertension, Primary Open Angle Glaucoma | Phase 1 | Completed | ForSight Vision5, Inc. | 14 | 2013-10-01 | 2014-12-17 |
| Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3 - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Unknown | Altheos, Inc. | 180 | 2012-01-01 | 2012-11-01 |
| EXTERNAL SLT Treatment in Patients With Uncontrolled OPEN ANGLE GLAUCOMA external slt, standard slt - Primary Open Angle Glaucoma | Phase 1 | Completed | Meir Medical Center | 32 | 2011-09-01 | 2014-08-12 |
| Safety and Efficacy Study of the Hydrus Aqueous Implant in Subjects With POAG prestudy topical glaucoma medications - Primary Open Angle Glaucoma | Phase 1 / Phase 2 | Completed | Ivantis, Inc. | 120 | 2010-03-01 | 2019-02-04 |
| Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma Epigallocatechin-gallate - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Unknown | Catholic University of the Sacred Heart | 40 | 2006-11-01 | 2007-05-21 |
Glaucoma, Open-Angle (9) · Ocular Hypertension (5) · Glaucoma (4) · Exfoliation Syndrome (1) · Low Tension Glaucoma (1)
Eye Diseases (9) · Glaucoma (5) · Ocular Hypertension (4) · Iris Diseases (1) · Optic Nerve Diseases (1) · Uveal Diseases (1)
ISTH0036 (1) · Insulin (1) · Timolol (1) · Trabeculectomy (1) · epigallocatechin gallate (1)
Aerpio Therapeutics (1) · Altheos, Inc. (1) · American Society Of Thermalism And Climatology Inc (1) · Catholic University of the Sacred Heart (1) · ForSight Vision5, Inc. (1) · Isarna Therapeutics GmbH (1) · Ivantis, Inc. (1) · Meir Medical Center (1) · Stanford University (1)
United States (4) · Germany (2) · Austria (1) · Israel (1) · Italy (1) · Latvia (1) · Mexico (1)
Anne Rubin (1) · Barbara Wirostko, MD (1) · Benedetto Falsini, MD (1) · Dario Marangoni, M.D. (1) · Ehud Asia, Prof. (1) · Garis Silega (1) · Jeffrey L Goldberg, MD PhD (1) · Michael Belkin, Prof. (1) · Noa Gefen, Dr. (1) · Petra Fettes, PhD (1) · Prof. Dr. Manfred Tetz, MD (1) · Tommaso Salgarello, M.D. (1)
2014 (1)